Corcept Therapeutics Incorporated Financial Ratios
CORT / Health Care|FY2025 SEC 10-K data
Includes DuPont ROE decomposition, profitability margins, liquidity ratios, solvency indicators, and earnings quality analysis. All ratios calculated from FY2025 SEC 10-K data.
Key Data Points
- Altman Z-Score 3.44 (safe zone, above 2.9 threshold)
- Strong profit margin: 20.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
DuPont ROE Decomposition (FY2025)
Return on Equity
15.4%
Profit Margin
13.1%
Net Income / Revenue
Asset Turnover
0.91
Revenue / Total Assets
Equity Multiplier
1.29
Total Assets / Equity
Composite: 15.4% (reported: 15.4%)
Profitability
Liquidity
Current Ratio
2.92
Quick Ratio
2.85
Solvency
Interest Coverage
-
Efficiency
Asset Turnover
0.91
Inventory Turnover
1.01
Days Sales Outstanding
29 days
As of FY2025 · SEC 10-K · Updated Jun 30, 2026
Earnings Quality
Accrual Ratio
-5.1%
+1.7pp YoY
Earnings are primarily supported by operating cash flow.
This metric is for informational purposes only and does not constitute investment advice. Data sourced from SEC EDGAR filings; updates may be delayed.